For instance, the RAD16-II self-assembling peptide nanogel has been employed for the intramyocardial delivery of platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), aimed at promoting revascularization in the myocardial infarction areas of rats and pigs, while effectively avoiding issues such as pulmonary hypertension caused by the systemic administration of PDGF [13,14]. This evidence concerns the gene VEGFA and pulmonary hypertension.